Malaria vaccine adjuvants: Latest update and challenges in preclinical and clinical research

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mata, Elena ^a   Salvador, Aiala ^a,b   Igartua, Manoli ^a,b   Hernández, Rosa María ^a,b   Pedraz, José Luis ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; LIPOSOME; MALARIA VACCINE; POLYSACCHARIDE; VIRUS VECTOR; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ADENOVIRUS; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; IMMUNIZATION; MALARIA; NONHUMAN; POXVIRUS; REVIEW; IMMUNOLOGY; MEDICAL RESEARCH; PARASITOLOGY; PATHOGENICITY; PLASMODIUM FALCIPARUM;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, PROTOZOAN; BIOMEDICAL RESEARCH; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84878144688     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/282913     Document Type: Review

References (208)

1. Girard M. P., Reed Z. H., Friede M., Kieny M. P., A review of human vaccine research and development: malaria. Vaccine 2007 25 9 1567 1580 2-s2.0-33846256606 10.1016/j.vaccine.2006.09.074 (Pubitemid 46108198)
2. Aide P., Aponte J. J., Renom M., Nhampossa T., Sacarlal J., Mandomando I., Bassat Q., Manaca M. N., Leach A., Lievens M., Vekemans J., Dubois M. C., Loucq C., Ripley Ballou W., Cohen J., Alonso P. L., Safety, immunogenicity and duration of protection of the RTS,S/ASO2D malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS ONE 2010 5 11 2-s2.0-78149488576 10.1371/journal.pone.0013838 e13838
3. Agnandji S. T., Lell B., Fernandes J. F., A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. New England Journal of Medicine 2012 367 24 2284 2295
4. De Gregorio E., Tritto E., Rappuoli R., Alum adjuvanticity: unraveling a century old mystery. European Journal of Immunology 2008 38 8 2068 2071 2-s2.0-51149090409 10.1002/eji.200838648
5. Baylor N. W., Egan W., Richman P., Aluminum salts in vaccines-US perspective. Vaccine 2002 20 3 S18 S23 2-s2.0-0037205207 10.1016/S0264-410X(02) 00166-4 (Pubitemid 34607671)
6. Brewer J. M., Conacher M., Hunter C. A., Mohrs M., Brombacher F., Alexander J., Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. Journal of Immunology 1999 163 12 6448 6454 2-s2.0-0032756730
7. Kool M., Soullié T., Van Nimwegen M., Willart M. A. M., Muskens F., Jung S., Hoogsteden H. C., Hammad H., Lambrecht B. N., Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. Journal of Experimental Medicine 2008 205 4 869 882 2-s2.0-42249088234 10.1084/jem.20071087 (Pubitemid 351549884)
8. Glenny A. T., Buttle A. H., Stevens M. F., Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. Journal of Pathology and Bacteriology 1932 34 267 275
9. Holt L. B., Developments in Diphtheria Prophylaxis 1950 W. Heinemann
10. Gupta R. K., Chang A. C., Griffin P., Rivera R., Siber G., In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 1996 14 1412 1416 (Pubitemid 27010310)
11. Weissburg R. P., Berman P. W., Cleland J. L., Eastman D., Farina F., Frie S., Lim A., Mordenti J., Nguyen T. T., Peterson M. R., Yim K., Powell M. F., Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharmaceutical Research 1995 12 1439 1446
12. Mannhalter J. W., Neychev H. O., Zlabinger G. J., Ahmad R., Eibl M. M., Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clinical and Experimental Immunology 1985 61 1 143 151 2-s2.0-0021828474 (Pubitemid 15029859)
13. Morefield G. L., Sokolovska A., Jiang D., Hogenesch H., Robinson J. P., Hem S. L., Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005 23 13 1588 1595 2-s2.0-13444292001 10.1016/j.vaccine.2004.07.050 (Pubitemid 40203396)
14. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L. Å., The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infection and Immunity 2001 69 2 1151 1159 2-s2.0-0035144140 10.1128/IAI.69.2.1151-1159.2001 (Pubitemid 32109584)
15. Rimaniol A. C., Gras G., Verdier F., Capel F., Grigoriev V. B., Porcheray F., Sauzeat E., Fournier J. G., Clayette P., Siegrist C. A., Dormont D., Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004 22 23-24 3127 3135 2-s2.0-3843097243 10.1016/j.vaccine.2004.01.061 (Pubitemid 39037217)
16. Jordan M. B., Mills D. M., Kappler J., Marrack P., Cambier J. C., Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 2004 304 5678 1808 1810 2-s2.0-2942701975 10.1126/science.1089926 (Pubitemid 38787898)
17. Eisenbarth S. C., Colegio O. R., O'Connor W., Sutterwala F. S., Flavell R. A., Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008 453 7198 1122 1126 2-s2.0-45749111446 10.1038/nature06939 (Pubitemid 351871731)
18. Kool M., Pétrilli V., De Smedt T., Rolaz A., Hammad H., Van Nimwegen M., Bergen I. M., Castillo R., Lambrecht B. N., Tschopp J., Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. Journal of Immunology 2008 181 6 3755 3759 2-s2.0-56149119563
19. Franchi L., Núñez G., The Nlrp3 inflammasome is critical for aluminum hydroxide-mediated IL-1 β secretion but dispensable for adjuvant activity. European Journal of Immunology 2008 38 8 2085 2089 2-s2.0-50849112477 10.1002/eji.200838549
20. McKee A. S., Munks M. W., MacLeod M. K. L., Fleenor C. J., Van Rooijen N., Kappler J. W., Marrack P., Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. Journal of Immunology 2009 183 7 4403 4414 2-s2.0-70449713915 10.4049/jimmunol.0900164
21. Patarroyo M. E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., Tascon R., Franco A., Murillo L. A., Ponton G., Trujillo G., A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988 332 6160 158 161 2-s2.0-0023871934 (Pubitemid 18083560)
22. Graves P., Gelband H., Vaccines for preventing malaria (SPf66). Cochrane Database of Systematic Reviews 2006 2 CD005966 2-s2.0-33745026946
23. + T lymphocyte immune response in humans. Implications for vaccination strategies. European Journal of Immunology 2001 31 7 1989 1998 (Pubitemid 32640714)
24. Ellis R. D., Martin L. B., Shaffer D., Long C. A., Miura K., Fay M. P., Narum D. L., Zhu D., Mullen G. E., Mahanty S., Miller L. H., Durbin A. P., Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PloS ONE 2010 5 1, article e8787 2-s2.0-77952512371 10.1371/journal.pone.0008787
25. Roestenberg M., Remarque E., de Jonge E., Hermsen R., Blythman H., Leroy O., Imoukhuede E., Jepsen S., Ofori-Anyinam O., Faber B., Kocken C. H. M., Arnold M., Walraven V., Teelen K., Roeffen W., de Mast Q., Ballou W. R., Cohen J., Dubois M. C., Ascarateil S., van der Ven A., Thomas A., Sauerwein R., Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel ™ Montanide ISA 720 or AS02. PLoS ONE 2008 3 12 2-s2.0-58049090288 10.1371/journal.pone.0003960 e3960
26. Sagara I., Dicko A., Ellis R. D., Fay M. P., Diawara S. I., Assadou M. H., Sissoko M. S., Kone M., Diallo A. I., Saye R., Guindo M. A., Kante O., Niambele M. B., Miura K., Mullen G. E. D., Pierce M., Martin L. B., Dolo A., Diallo D. A., Doumbo O. K., Miller L. H., Saul A., A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009 27 23 3090 3098 2-s2.0-67349273039 10.1016/j.vaccine.2009.03. 014
27. Hermsen C. C., Verhage D. F., Telgt D. S. C., Teelen K., Bousema J. T., Roestenberg M., Bolad A., Berzins K., Corradin G., Leroy O., Theisen M., Sauerwein R. W., Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007 25 15 2930 2940 2-s2.0-33947107414 10.1016/j.vaccine.2006.06.081 (Pubitemid 46412561)
28. El Sahly H. M., Patel S. M., Atmar R. L., Lanford T. A., Dube T., Thompson D., Sim B. K. L., Long C., Keitel W. A., Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clinical and Vaccine Immunology 2010 17 10 1552 1559 2-s2.0-77957872219 10.1128/CVI.00082-10
29. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., Druilhe P., Spertini F., Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and Immunity 2005 73 12 8017 8026 2-s2.0-28444478057 10.1128/IAI.73.12.8017-8026.2005 (Pubitemid 41740288)
30. Lusingu J. P., Gesase S., Msham S., Francis F., Lemnge M., Seth M., Sembuche S., Rutta A., Minja D., Segeja M. D., Bosomprah S., Cousens S., Noor R., Chilengi R., Druilhe P., Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malaria Journal 2009 8 1, article 163 2-s2.0-68949088772 10.1186/1475-2875-8-163
31. Esen M., Kremsner P. G., Schleucher R., Gässler M., Imoukhuede E. B., Imbault N., Leroy O., Jepsen S., Knudsen B. W., Schumm M., Knobloch J., Theisen M., Mordmüller B., Safety and immunogenicity of GMZ2-a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 2009 27 49 6862 6868 2-s2.0-70350786394 10.1016/j.vaccine.2009.09.011
32. Horii T., Shirai H., Jie L., Ishii K. J., Palacpac N. Q., Tougan T., Hato M., Ohta N., Bobogare A., Arakaki N., Matsumoto Y., Namazue J., Ishikawa T., Ueda S., Takahashi M., Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitology International 2010 59 3 380 386 2-s2.0-77955329010 10.1016/j.parint.2010.05.002
33. Kaslow D. C., Transmission-blocking vaccines. Chemical Immunology 2002 80 287 307 2-s2.0-0036090383 (Pubitemid 34516805)
34. Malkin E. M., Durbin A. P., Diemert D. J., Sattabongkot J., Wu Y., Miura K., Long C. A., Lambert L., Miles A. P., Wang J., Stowers A., Miller L. H., Saul A., Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2005 23 24 3131 3138 2-s2.0-20144388434 10.1016/j.vaccine.2004.12.019
35. Initial study of Malaria Vaccine PFs25-EPA/Alhydrogel. 2012, http://www.clinicaltrials.gov/ct2/show/NCT01434381
36. Qian F., Wu Y., Muratova O., Zhou H., Dobrescu G., Duggan P., Lynn L., Song G., Zhang Y., Reiter K., MacDonald N., Narum D. L., Long C. A., Miller L. H., Saul A., Mullen G. E. D., Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine 2007 25 20 3923 3933 2-s2.0-34247220229 10.1016/j.vaccine.2007.02.073 (Pubitemid 46616999)
37. Ott G., Barchfeld G. L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G., MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharmaceutical biotechnology 1995 6 277 296 2-s2.0-0029177443
38. Wack A., Baudner B. C., Hilbert A. K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., O'Hagan D. T., Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008 26 4 552 561 2-s2.0-37849039132 10.1016/j.vaccine.2007.11.054
39. Corradin G., Del Giudice G., Novel adjuvants for vaccines. Current Medicinal Chemistry 2005 4 2 185 191 2-s2.0-14844343194 10.2174/1568014053507113 (Pubitemid 40352665)
40. Seubert A., Monaci E., Pizza M., O'hagan D. T., Wack A., The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells1. Journal of Immunology 2008 180 8 5402 5412 2-s2.0-45949083618
41. Yazdani S. S., Shakri A. R., Mukherjee P., Baniwal S. K., Chitnis C. E., Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 2004 22 27-28 3727 3737 2-s2.0-4143053637 10.1016/j.vaccine.2004.03.030 (Pubitemid 39099649)
42. Sachdeva S., Mohmmed A., Dasaradhi P. V. N., Crabb B. S., Katyal A., Malhotra P., Chauhan V. S., Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-142 using human compatible adjuvants. Vaccine 2006 24 12 2007 2016 2-s2.0-32844458999 10.1016/j.vaccine.2005.11.041 (Pubitemid 43255141)
43. Stowers A. W., Cioce V., Shimp R. L., Lawson M., Hui G., Muratova O., Kaslow D. C., Robinson R., Long C. A., Miller L. H., Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infection and Immunity 2001 69 3 1536 1546 2-s2.0-0035115020 10.1128/IAI.69.3.1536-1546.2001 (Pubitemid 32187606)
44. Inselburg J., Bathurst I. C., Kansopon J., Barr P. J., Rossan R., Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infection and Immunity 1993 61 5 2048 2052 2-s2.0-0027172742 (Pubitemid 23145912)
45. Roman F., Clément F., Dewé W., Walravens K., Maes C., Willekens J., De Boever F., Hanon E., Leroux-Roels G., Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clinical and Vaccine Immunology 2011 18 5 835 843 2-s2.0-79955717327 10.1128/CVI.00480-10
46. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., Planty C., Elouahabi A., Harvengt P., Carlsen H., Kielland A., Chomez P., Garçon N., Van Mechelen M., Adjuvant System AS03 containing α -tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011 29 13 2461 2473 2-s2.0-79952362612 10.1016/j.vaccine. 2011.01.011
47. Mohr E., Serre K., Manz R. A., Cunningham A. F., Khan M., Hardie D. L., Bird R., MacLennan I. C. M., Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. Journal of Immunology 2009 182 4 2113 2123 2-s2.0-61449162967 10.4049/jimmunol.0802771
48. Stoute J. A., Slaoui M., Heppner D. G., Momin P., Kester K. E., Desmons P., Wellde B. T., Garçon N., Krzych U., Marchand M., Ballou W. R., Cohen J. D., A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New England Journal of Medicine 1997 336 2 86 91 2-s2.0-0004170486 10.1056/NEJM199701093360202 (Pubitemid 27020884)
49. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V., Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Review of Vaccines 2002 1 1 111 118 2-s2.0-0038176089 10.1586/14760584.1.1.111 (Pubitemid 36686885)
50. Benmohamed L., Thomas A., Bossus M., Brahimi K., Wubben J., Gras-Masse H., Druilhe P., High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 2000 18 25 2843 2855 2-s2.0-0034659607 (Pubitemid 30254472)
51. Aucouturier J., Dupuis L., Ganne V., Adjuvants designed for veterinary and human vaccines. Vaccine 2001 19 17-19 2666 2672 2-s2.0-0035925593 10.1016/S0264-410X(00)00498-9 (Pubitemid 32234287)
52. Genton B., D'Acremont V., Lurati-Ruiz F., Verhage D., Audran R., Hermsen C., Wolters L., Reymond C., Spertini F., Sauerwein R., Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine 2010 28 40 6573 6580 2-s2.0-77956399020 10.1016/j.vaccine.2010.07.067
53. Daubersies P., Ollomo B., Sauzet J. P., Brahimi K., Perlaza B. L., Eling W., Moukana H., Rouquet P., de Taisne C., Druilhe P., Genetic immunisation by liver stage antigen 3 protects chimpanzees against malaria despite low immune responses. PLoS ONE 2008 3 7 2-s2.0-50549091750 10.1371/journal.pone.0002659 e2659
54. Genton B., Al-Yaman F., Betuela I., Anders R. F., Saul A., Baea K., Mellombo M., Taraika J., Brown G. V., Pye D., Irving D. O., Felger I., Beck H. P., Smith T. A., Alpers M. P., Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003 22 1 30 41 2-s2.0-10744225159 10.1016/S0264-410X(03)00536-X (Pubitemid 37357150)
55. Lawrence G., Cheng Q., Reed C., Taylor D., Stowers A., Cloonan N., Rzepczyk C., Smillie A., Anderson K., Pombo D., Allworth A., Eisen D., Anders R., Saul A., Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000 18 18 1925 1931 2-s2.0-0034001440 10.1016/S0264- 410X(99)00444-2 (Pubitemid 30122856)
56. Malkin E., Hu J., Li Z., Chen Z., Bi X., Reed Z., Dubovsky F., Liu J., Wang Q., Pan X., Chen T., Giersing B., Xu Y., Kang X., Gu J., Shen Q., Tucker K., Tierney E., Pan W., Long C., Cao Z., A Phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008 26 52 6864 6873 2-s2.0-56949090515 10.1016/j.vaccine.2008. 09.081
57. Pierce M. A., Ellis R. D., Martin L. B., Malkin E., Tierney E., Miura K., Fay M. P., Marjason J., Elliott S. L., Mullen G. E. D., Rausch K., Zhu D., Long C. A., Miller L. H., Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 2010 28 10 2236 2242 2-s2.0-77049125460 10.1016/j.vaccine.2009.12.049
58. McCarthy J. S., Marjason J., Elliott S., A phase 1 trial of a bivalent MSP2 blod-stage malaria vaccine formulated with Montanide ISA 720. 1076 Abstracts Book of the American Society of Tropical Medicine and Hygiene 57th Annual Meeting 2008
59. Wu Y., Ellis R. D., Shaffer D., Fontes E., Malkin E. M., Mahanty S., Fay M. P., Narum D., Rausch K., Miles A. P., Aebig J., Orcutt A., Muratova O., Song G., Lambert L., Zhu D., Miura K., Long C., Saul A., Miller L. H., Durbin A. P., Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs 25 formulated with montanide ISA 51. PLoS ONE 2008 3 7 2-s2.0-49949097129 10.1371/journal.pone.0002636 e2636
60. Carlson B. C., Jansson A. M., Larsson A., Bucht A., Lorentzen J. C., The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. American Journal of Pathology 2000 156 6 2057 2065 2-s2.0-0033872729 (Pubitemid 30641773)
61. Sun H. X., Xie Y., Ye Y. P., Advances in saponin-based adjuvants. Vaccine 2009 27 12 1787 1796 2-s2.0-61349084783 10.1016/j.vaccine.2009.01.091
62. Dalsgaard K., A study of the isolation and characterization of the saponin Quil A. Evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle against foot-and-mouth disease. Acta veterinaria Scandinavica 1978 69 7 40 2-s2.0-0018112670
63. Waite D. C., Jacobson E. W., Ennis F. A., Edelman R., White B., Kammer R., Anderson C., Kensil C. R., Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001 19 28-29 3957 3967 2-s2.0-0035898945 10.1016/S0264-410X(01) 00142-6 (Pubitemid 32566320)
64. Rajput Z. I., Hu S. H., Xiao C. W., Arijo A. G., Adjuvant effects of saponins on animal immune responses. Journal of Zhejiang University. Science B 2007 8 3 153 161 2-s2.0-34247117348 10.1631/jzus.2007.B0153
65. Glauert A. M., Dingle J. T., Lucy J. A., Action of saponin on biological cell membranes. Nature 1962 196 4858 953 955 2-s2.0-37049052069 10.1038/196953a0
66. Kashala O., Amador R., Valero M. V., Moreno A., Barbosa A., Nickel B., Daubenberger C. A., Guzman F., Pluschke G., Patarroyo M. E., Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine 2002 20 17-18 2263 2277 2-s2.0-0037157260 10.1016/S0264-410X(02)00115-9 (Pubitemid 34497037)
67. Kersten G. F. A., Crommelin D. J. A., Liposomes and ISCOMs. Vaccine 2003 21 9-10 915 920 2-s2.0-0037435928 10.1016/S0264-410X(02)00540-6 (Pubitemid 36126426)
68. Coulter A., Harris R., Davis R., Drane D., Cox J., Ryan D., Sutton P., Rockman S., Pearse M., Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003 21 9-10 946 949 2-s2.0-0037435982 10.1016/S0264-410X(02)00545-5 (Pubitemid 36126429)
69. Pearse M. J., Drane D., ISCOMATRIX adjuvant for antigen delivery. Advanced Drug Delivery Reviews 2005 57 3 465 474 2-s2.0-9244230047 10.1016/j.addr.2004.09.006 (Pubitemid 39550971)
70. Furrie E., Smith R. E., Turner M. W., Strobel S., Mowat A. M., Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS). Vaccine 2002 20 17-18 2254 2262 2-s2.0-0037157264 10.1016/S0264- 410X(02)00106-8 (Pubitemid 34497036)
71. Lockyer M. J., Cooper H., Tite J., Rowan W., Crowe J. S., Immunogenicity of a hybrid Plasmodium falciparum malaria antigen. Parasitology 1993 106 5 451 457 2-s2.0-0027191327 (Pubitemid 23169805)
72. Sjolander A., Hansson M., Lovgren K., Wahlin B., Berzsins K., Perlmann P., Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparum antigen Pf155/RESA. Parasite Immunology 1993 15 6 355 359 2-s2.0-0027177022 (Pubitemid 23202088)
73. Chopra N., Biswas S., Thomas B., Sabhnani L., Rao D. N., Inducing protective antibodies against ring-infected erythrocyte surface peptide antigen of Plasmodium falciparum using immunostimulating complex (ISCOMS) delivery. Medical Microbiology and Immunology 2000 189 2 75 83 2-s2.0-0033663003 10.1007/s004300000042
74. + T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Vaccine 2005 23 21 2801 2812 2-s2.0-15044347193 10.1016/j.vaccine.2004.10.044 (Pubitemid 40381274)
75. Grgacic E. V. L., Anderson D. A., Virus-like particles: passport to immune recognition. Methods 2006 40 1 60 65 2-s2.0-33748794562 10.1016/j.ymeth.2006.07.018 (Pubitemid 44415499)
76. Kündig T. M., Senti G., Schnetzler G., Wolf C., Prinz Vavricka B. M., Fulurija A., Hennecke F., Sladko K., Jennings G. T., Bachmann M. F., Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. Journal of Allergy and Clinical Immunology 2006 117 6 1470 1476 2-s2.0-33646949257 10.1016/j.jaci.2006.01.040 (Pubitemid 43795737)
77. Roth J. F., The yeast Ty virus-like particles. Yeast 2000 16 9 785 795
78. Reed S. G., Bertholet S., Coler R. N., Friede M., New horizons in adjuvants for vaccine development. Trends in Immunology 2009 30 1 23 32 2-s2.0-58149216348 10.1016/j.it.2008.09.006
79. Gregson A. L., Oliveira G., Othoro C., Calvo-Calle J. M., Thorton G. B., Nardin E., Edelman R., Phase I trial of an Alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS ONE 2008 3 2 2-s2.0-45249093689 10.1371/journal.pone.0001556 e1556 (Pubitemid 351836831)
80. Walther M., Dunachie S., Keating S., Vuola J. M., Berthoud T., Schmidt A., Maier C., Andrews L., Andersen R. F., Gilbert S., Poulton I., Webster D., Dubovsky F., Tierney E., Sarpotdar P., Correa S., Huntcooke A., Butcher G., Williams J., Sinden R. E., Thornton G. B., Hill A. V. S., Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 2005 23 7 857 864 2-s2.0-10444286628 10.1016/j.vaccine.2004.08.020 (Pubitemid 39643172)
81. Gordon D. M., McGovern T. W., Krzych U., Cohen J. C., Schneider I., LaChance R., Heppner D. G., Yuan G., Hollingdale M., Slaoui M., Hauser P., Voet P., Sadoff J. C., Ballou W. R., Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. Journal of Infectious Diseases 1995 171 6 1576 1585 2-s2.0-0029057169
82. Da Silva D. M., Pastrana D. V., Schiller J. T., Kast W. M., Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 2001 290 2 350 360 2-s2.0-0035950924 10.1006/viro.2001.1179 (Pubitemid 33141236)
83. Takeda K., Akira S., Toll-like receptors in innate immunity. International Immunology 2005 17 1 1 14 2-s2.0-12444341944 10.1093/intimm/dxh186
84. Medzhitov R., Janeway C. Jr., Advances in immunology: innate immunity. New England Journal of Medicine 2000 343 5 338 344 2-s2.0-0034601309 10.1056/NEJM200008033430506 (Pubitemid 30616701)
85. Medzhitov R., Toll-like receptors and innate immunity. Nature Reviews Immunology 2001 1 2 135 145 2-s2.0-0035524488 (Pubitemid 33741967)
86. Kumagai Y., Akira S., Identification and functions of pattern-recognition receptors. Journal of Allergy and Clinical Immunology 2010 125 5 985 992 2-s2.0-77951877953 10.1016/j.jaci.2010.01.058
87. O'Neill L. A. J., Bowie A. G., The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology 2007 7 5 353 364 2-s2.0-34247566510 10.1038/nri2079 (Pubitemid 46674493)
88. Kumar H., Kawai T., Akira S., Toll-like receptors and innate immunity. Biochemical and Biophysical Research Communications 2009 388 4 621 625 2-s2.0-69949140723 10.1016/j.bbrc.2009.08.062
89. Hedayat M., Netea M. G., Rezaei N., Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infectious Diseases 2011 11 9 702 712
90. Lahiri A., Das P., Chakravortty D., Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008 26 52 6777 6783 2-s2.0-56649108016 10.1016/j.vaccine.2008.09.045
91. Pasare C., Medzhitov R., Toll-like receptors: linking innate and adaptive immunity. Microbes and Infection 2004 6 15 1382 1387 2-s2.0-16644366474 10.1016/j.micinf.2004.08.018 (Pubitemid 41110581)
92. Casares S., Brumeanu T. D., Richie T. L., The RTS,S malaria vaccine. Vaccine 2010 28 31 4880 4894 2-s2.0-77954762106 10.1016/j.vaccine.2010.05.033
93. Beran J., Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opinion on Biological Therapy 2008 8 2 235 247 2-s2.0-38949119533 10.1517/14712598.8.2.235 (Pubitemid 351233716)
94. Leroux-Rouls G., Moreaux E., Desombre I., Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1994 Washington, DC, USA American Society for Microbiology 205
95. Tielemans C. L., Vlasak J., Kosa D., Billiouw J. M., Verpooten G. A., Mezei I., Ryba M., Peeters P. C., Mat O., Jadoul M. Y., Polakovic V., Dhaene M., Treille S., Kuriyakose S. O., Leyssen M., Houard S. A., Surquin M., Immunogenicity and safety of an investigational AS02v-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011 29 6 1159 1166 2-s2.0-78751581622 10.1016/j.vaccine.2010.12.009
96. Denoël P., Philipp M. T., Doyle L., Martin D., Carletti G., Poolman J. T., A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011 29 33 5495 5501 2-s2.0-79960342392 10.1016/j.vaccine.2011.05.051
97. Cluff C. W., Monophosphoryl lipid a (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Advances in Experimental Medicine and Biology 2010 667 111 123 2-s2.0-77952540334 10.1007/978-1-4419-1603-7-10
98. Audran R., Lurati-Ruiz F., Genton B., Blythman H. E., Ofori-Anyinam O., Reymond C., Corradin G., Spertini F., The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial. PLoS ONE 2009 4 10 2-s2.0-70350135532 10.1371/journal.pone.0007304 e7304
99. Cummings J. F., Spring M. D., Schwenk R. J., Ockenhouse C. F., Kester K. E., Polhemus M. E., Walsh D. S., Yoon I. K., Prosperi C., Juompan L. Y., Lanar D. E., Krzych U., Hall B. T., Ware L. A., Stewart V. A., Williams J., Dowler M., Nielsen R. K., Hillier C. J., Giersing B. K., Dubovsky F., Malkin E., Tucker K., Dubois M. C., Cohen J. D., Ballou W. R., Heppner G., Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN- γ /IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 2010 28 31 5135 5144 2-s2.0-77954760139 10.1016/j.vaccine.2009.08.046
100. Kester K. E., Cummings J. F., Ofori-Anyinam O., Ockenhouse C. F., Krzych U., Moris P., Schwenk R., Nielsen R. A., Debebe Z., Pinelis E., Juompan L., Williams J., Dowler M., Stewart V. A., Wirtz R. A., Dubois M. C., Lievens M., Cohen J., Ballou W. R., Heppner D. G., Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. Journal of Infectious Diseases 2009 200 3 337 346 2-s2.0-67650699591 10.1086/600120
101. Bojang K. A., Milligan P. J. M., Pinder M., Vigneron L., Alloueche A., Kester K. E., Ballou W. R., Conway D. J., Reece W. H. H., Gothard P., Yamuah L., Delchambre M., Voss G., Greenwood B. M., Hill A., McAdam K. P. W. J., Tornieporth N., Cohen J. D., Doherty T., Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001 358 9297 1927 1934 2-s2.0-0035830278 10.1016/S0140-6736(01)06957-4 (Pubitemid 34072872)
102. Polhemus M. E., Remich S. A., Ogutu B. R., Waitumbi J. N., Otieno L., Apollo S., Cummings J. F., Kester K. E., Ockenhouse C. F., Stewart A., Ofori-Anyinam O., Ramboer I., Cahill C. P., Lievens M., Dubois M. C., Demoitie M. A., Leach A., Cohen J., Ballou R. W., Heppner G. D., Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 2009 4 7 2-s2.0-68149092706 10.1371/journal.pone.0006465 e6465
103. Sacarlal J., Aide P., Aponte J. J., Renom M., Leach A., Mandomando I., Lievens M., Bassat Q., Lafuente S., Macete E., Vekemans J., Guinovart C., Sigaúuque B., Sillman M., Milman J., Dubois M. C., Demoitié M. A., Thonnard J., Menéndez C., Ballou W. R., Cohen J., Alonso P. L., Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in mozambican children. Journal of Infectious Diseases 2009 200 3 329 336 2-s2.0-67650697101 10.1086/600119
104. Aponte J. J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., Manaca M. N., Lafuente S., Barbosa A., Leach A., Lievens M., Vekemans J., Sigauque B., Dubois M. C., Demoitié M. A., Sillman M., Savarese B., McNeil J. G., Macete E., Ballou W. R., Cohen J., Alonso P. L., Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007 370 9598 1543 1551 2-s2.0-35548999572 10.1016/S0140-6736(07)61542-6 (Pubitemid 350018877)
105. Ogutu B. R., Apollo O. J., McKinney D., Okoth W., Siangla J., Dubovsky F., Tucker K., Waitumbi J. N., Diggs C., Wittes J., Malkin E., Leach A., Soisson L. A., Milman J. B., Otieno L., Holland C. A., Polhemus M., Remich S. A., Ockenhouse C. F., Cohen J., Ballou W. R., Martin S. K., Angov E., Stewart V. A., Lyon J. A., Heppner D. G., Withers M. R., Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 2009 4 3 2-s2.0-61849177531 10.1371/journal.pone.0004708 e4708
106. Thera M. A., Doumbo O. K., Coulibaly D., Laurens M. B., Kone A. K., Guindo A. B., Traore K., Sissoko M., Diallo D. A., Diarra I., Kouriba B., Daou M., Dolo A., Baby M., Sissoko M. S., Sagara I., Niangaly A., Traore I., Olotu A., Godeaux O., Leach A., Dubois M. C., Ballou W. R., Cohen J., Thompson D., Dube T., Soisson L., Diggs C. L., Takala S. L., Lyke K. E., House B., Lanar D. E., Dutta S., Heppner D. G., Plowe C. V., Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS ONE 2010 5 2 2-s2.0-77649084917 10.1371/journal.pone.0009041 e9041
107. Spring M. D., Cummings J. F., Ockenhouse C. F., Dutta S., Reidler R., Angov E., Bergmann-Leitner E., Stewart V. A., Bittner S., Juompan L., Kortepeter M. G., Nielsen R., Krzych U., Tierney E., Ware L. A., Dowler M., Hermsen C. C., Sauerwein R. W., de Vlas S. J., Ofori-Anyinam O., Lanar D. E., Williams J. L., Kester K. E., Tucker K., Shi M., Malkin E., Long C., Diggs C. L., Soisson L., Duboiss M. C., Ballou W. R., Cohen J., Heppner D. G., Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-l) administered in adjuvant system AS01B or AS02A. PLoS ONE 2009 4 4 2-s2.0-65449181983 10.1371/journal.pone.0005254 e5254
108. Forgus S., Leroux-Roels I., De Boeve F., Safety and immunogenicity of the M72/AS01B and M72/AS02A candidate tuberculosis vaccines in PPD-negative Belgian adults. TBV 2008-TB Vaccines For the World 2008
109. + T cell responses in seronegative volunteers. Clinical Infectious Diseases 2011 52 4 522 531 2-s2.0-79951823624 10.1093/cid/ciq160
110. Mettens P., Dubois P. M., Demoitié M. A., Bayat B., Donner M. N., Bourguignon P., Stewart V. A., Heppner D. G., Garçon N., Cohen J., Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 2008 26 8 1072 1082 2-s2.0-39149099786 10.1016/j.vaccine.2007.12.018
111. Shott J. P., McGrath S. M., Pau M. G., Custers J. H. V., Ophorst O., Demoitié M. A., Dubois M. C., Komisar J., Cobb M., Kester K. E., Dubois P., Cohen J., Goudsmit J., Heppner D. G., Stewart V. A., Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN- γ and antibody responses in mice. Vaccine 2008 26 23 2818 2823 2-s2.0-43249109767 10.1016/j.vaccine.2008.03.080
112. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., Mshamu S., Lang T., Gould J., Dubois M. C., Demoitié M. A., Stallaert J. F., Vansadia P., Carter T., Njuguna P., Awuondo K. O., Malabeja A., Abdul O., Gesase S., Mturi N., Drakeley C. J., Savarese B., Villafana T., Ballou W. R., Cohen J., Riley E. M., Lemnge M. M., Marsh K., Von Seidlein L., Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. New England Journal of Medicine 2008 359 24 2521 2532 2-s2.0-57649115306 10.1056/NEJMoa0807381
113. Agnandji S. T., Lell B., Soulanoudjingar S. S., First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. New England Journal of Medicine 2011 365 20 1863 1875
114. Krieg A. M., CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology 2002 20 709 760 2-s2.0-0036219195 10.1146/annurev.immunol. 20.100301.064842 (Pubitemid 34293438)
115. Harandi A. M., Holmgren J., CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Current Opinion in Investigational Drugs 2004 5 2 141 145 2-s2.0-3042725534
116. Krieg A. M., Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides. Current Oncology Reports 2004 6 2 88 95 2-s2.0-2342558523 (Pubitemid 38898835)
117. Gupta G. K., Agrawal D. K., CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. BioDrugs 2010 24 4 225 235 2-s2.0-77954589298 10.2165/11536140-000000000-00000
118. Sagara I., Ellis R. D., Dicko A., Niambele M. B., Kamate B., Guindo O., Sissoko M. S., Fay M. P., Guindo M. A., Kante O., Saye R., Miura K., Long C., Mullen G. E. D., Pierce M., Martin L. B., Rausch K., Dolo A., Diallo D. A., Miller L. H., Doumbo O. K., A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 2009 27 52 7292 7298 2-s2.0-70849089713 10.1016/j.vaccine.2009.10.087
119. Traore B., Koné Y., Doumbo S., Doumtabé D., Traoré A., Crompton P. D., Mircetic M., Huang C. Y., Kayentao K., Dicko A., Sagara I., Ellis R. D., Miura K., Guindo A., Miller L. H., Doumbo O. K., Pierce S. K., The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum -specific memory B cells in semi-immune adults in Mali. Vaccine 2009 27 52 7299 7303 2-s2.0-70649098244 10.1016/j.vaccine.2009.08.023
120. Ellis R. D., Wu Y., Martin L. B., Phase 1 study in malaria naive adults of BSAM2/Alhydrogel+CPG 7909, a blood stage vaccine against P. falciparum malaria. PLoS One 2012 7 10 e46094
121. Klinman D. M., Klaschik S., Sato T., Tross D., CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Advanced Drug Delivery Reviews 2009 61 3 248 255 2-s2.0-61749101130 10.1016/j.addr.2008.12.012
122. Ichikawa H. T., Williams L. P., Segal B. M., Activation of APCs through CD40 or toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. Journal of Immunology 2002 169 5 2781 2787 2-s2.0-0036721808 (Pubitemid 34921028)
123. Peek L. J., Middaugh C. R., Berkland C., Nanotechnology in vaccine delivery. Advanced Drug Delivery Reviews 2008 60 8 915 928 2-s2.0-42649120973 10.1016/j.addr.2007.05.017
124. Glück R., Moser C., Metcalfe I. C., Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opinion on Biological Therapy 2004 4 7 1139 1145 2-s2.0-3142657967 10.1517/14712598.4.7.1139 (Pubitemid 38937555)
125. Glück R., Burri K. G., Metcalfe I., Adjuvant and antigen delivery properties of virosomes. Current Drug Delivery 2005 2 4 395 400 2-s2.0-24644505322 10.2174/156720105774370302 (Pubitemid 41277771)
126. Matlin K. S., Reggio H., Helenius A., Simons K., Infectious entry pathway of influenza virus in a canine kidney cell line. Journal of Cell Biology 1981 91 3 601 613 2-s2.0-0019814443 (Pubitemid 12211148)
127. Bungener L., Huckriede A., De Mare A., De Vries-Idema J., Wilschut J., Daemen T., Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 2005 23 10 1232 1241 2-s2.0-12344265748 10.1016/j.vaccine.2004.09.002 (Pubitemid 40126526)
128. Genton B., Pluschke G., Degen L., Kammer A. R., Westerfeld N., Okitsu S. L., Schroller S., Vounatsou P., Mueller M. M., Tanner M., Zurbriggen R., A randomized placebo-controlled phase la malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE 2007 2 10 2-s2.0-42449113669 10.1371/journal.pone.0001018 e1018 (Pubitemid 351560148)
129. Okitsu S. L., Silvie O., Westerfeld N., Curcic M., Kammer A. R., Mueller M. S., Sauerwein R. W., Robinson J. A., Genton B., Mazier D., Zurbriggen R., Pluschke G., A virosomal malaria Peptide vaccine elicits a longlasting sporozoite-inhibitory antibody response in a phase 1a clinical trail. PLoS ONE 2007 2 12 2-s2.0-40449085265 10.1371/journal.pone.0001278 e1278 (Pubitemid 351722474)
130. Thompson F. M., Porter D. W., Okitsu S. L., Westerfeld N., Vogel D., Todryk S., Poulton I., Correa S., Hutchings C., Berthoud T., Dunachie S., Andrews L., Williams J. L., Sinden R., Gilbert S. C., Pluschke G., Zurbriggen R., Hill A. V. S., Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 2008 3 1 2-s2.0-42949156106 10.1371/journal.pone.0001493 e1493 (Pubitemid 351827205)
131. Cavanagh D. R., Remarque E. J., Sauerwein R. W., Hermsen C. C., Luty A. J. F., Influenza virosomes: a flu jab for malaria? Trends in Parasitology 2008 24 9 382 385 2-s2.0-49449099166 10.1016/j.pt.2008.06.002
132. Brun A., Albina E., Barret T., Chapman D. A. G., Czub M., Dixon L. K., Keil G. M., Klonjkowski B., Le Potier M. F., Libeau G., Ortego J., Richardson J., Takamatsu H. H., Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems. Vaccine 2008 26 51 6508 6528 2-s2.0-58149191453 10.1016/j.vaccine.2008.09.044
133. Draper S. J., Heeney J. L., Viruses as vaccine vectors for infectious diseases and cancer. Nature Reviews Microbiology 2010 8 1 62 73 2-s2.0-73949116981 10.1038/nrmicro2240
134. Rollier C. S., Reyes-Sandoval A., Cottingham M. G., Ewer K., Hill A. V. S., Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology 2011 23 3 377 382 2-s2.0-79957761310 10.1016/j.coi.2011.03.006
135. Lee J. S., Hadjipanayis A. G., Parker M. D., Viral vectors for use in the development of biodefense vaccines. Advanced Drug Delivery Reviews 2005 57 9 1293 1314 2-s2.0-20444374148 10.1016/j.addr.2005.01.011 (Pubitemid 40796127)
136. Walther M., Thompson F. M., Dunachie S., Keating S., Todryk S., Berthoud T., Andrews L., Andersen R. F., Moore A., Gilbert S. C., Poulton I., Dubovsky F., Tierney E., Correa S., Huntcooke A., Butcher G., Williams J., Sinden R. E., Hill A. V. S., Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infection and Immunity 2006 74 5 2706 2716 2-s2.0-33646353667 10.1128/IAI.74.5.2706-2716.2006 (Pubitemid 43672979)
137. Dunachie S. J., Walther M., Epstein J. E., Keating S., Berthoud T., Andrews L., Andersen R. F., Bejon P., Goonetilleke N., Poulton I., Webster D. P., Butcher G., Watkins K., Sinden R. E., Levine G. L., Richie T. L., Schneider J., Kaslow D., Gilbert S. C., Carucci D. J., Hill A. V. S., A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and Immunity 2006 74 10 5933 5942 2-s2.0-33749235904 10.1128/IAI.00590-06 (Pubitemid 44484581)
138. Imoukhuede E. B., Berthoud T., Milligan P., Bojang K., Ismaili J., Keating S., Nwakanma D., Keita S., Njie F., Sowe M., Todryk S., Laidlaw S. M., Skinner M. A., Lang T., Gilbert S., Greenwood B. M., Hill A. V. S., Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine 2006 24 42-43 6526 6533 2-s2.0-33749449876 10.1016/j.vaccine.2006.06.022 (Pubitemid 44511860)
139. Vuola J. M., Keating S., Webster D. P., Berthoud T., Dunachie S., Gilbert S. C., Hill A. V. S., Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. Journal of Immunology 2005 174 1 449 455 2-s2.0-10844264174 (Pubitemid 40007434)
140. Bejon P., Ogada E., Mwangi T., Milligan P., Lang T., Fegan G., Gilbert S. C., Peshu N., Marsh K., Hill A. V., Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PloS ONE 2007 2 1, article e707 2-s2.0-77949323790
141. Prieur E., Gilbert S. C., Schneider J., Moore A. C., Sheu E. G., Goonetilleke N., Robson K. J. H., Hill A. V. S., A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proceedings of the National Academy of Sciences of the United States of America 2004 101 1 290 295 2-s2.0-0347088996 10.1073/pnas.0307158101 (Pubitemid 38084243)
142. Porter D. W., Thompson F. M., Berthoud T. K., A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011 29 43 7514 7522
143. Tamminga C., Sedegah M., Regis D., Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1-part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS ONE 2011 6 10 e25868
144. Li S., Locke E., Bruder J., Clarke D., Doolan D. L., Havenga M. J. E., Hill A. V. S., Liljestrom P., Monath T. P., Naim H. Y., Ockenhouse C., Tang D. C. C., Van Kampen K. R., Viret J. F., Zavala F., Dubovsky F., Viral vectors for malaria vaccine development. Vaccine 2007 25 14 2567 2574 2-s2.0-33947165743 10.1016/j.vaccine.2006.07.035 (Pubitemid 46400924)
145. Stewart V. A., McGrath S. M., Dubois P. M., Pau M. G., Mettens P., Shott J., Cobb M., Burge J. R., Larson D., Ware L. A., Demoitie M. A., Weverling G. J., Bayat B., Custers J. H. H. V., Dubois M. C., Cohen J., Goudsmit J., Heppner D. G., Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infection and Immunity 2007 75 5 2283 2290 2-s2.0-34248329578 10.1128/IAI.01879-06 (Pubitemid 46744316)
146. Radošević K., Rodriguez A., Lemckert A. A. C., Van Der Meer M., Gillissen G., Warnar C., Von Eyben R., Pau M. G., Goudsmit J., The Th1 Immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clinical and Vaccine Immunology 2010 17 11 1687 1694 2-s2.0-79551484182 10.1128/CVI.00554-10
147. 'Hara G. A. O., Duncan C. J., Ewer K. J., Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. Journal of Infectious Diseases 2012 205 5 772 781
148. A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS. 2012, http:// clinicaltrialsfeeds.org/clinical trials/show/NCT01623557
149. + T-cell responses. Infection and Immunity 2010 78 1 145 153 2-s2.0-73449147009 10.1128/IAI.00740-09
150. Capone S., Reyes-Sandoval A., Naddeo M., Siani L., Ammendola V., Rollier C. S., Nicosia A., Colloca S., Cortese R., Folgori A., Hill A. V. S., Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 2010 29 2 256 265 2-s2.0-78649714536 10.1016/j.vaccine.2010.10.041
151. Sheehy S. H., Duncan C. J., Elias S. C., Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Molecular Therapy 2011 19 12 2269 2276
152. Sheehy S. H., Duncan C. J. A., Elias S. C., Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 2012 7 2 e31208
153. Sheehy S. H., Duncan C. J., Elias S. C., ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Molecular Therapy 2012 20 12 2355 2368
154. Gregoriadis G., Immunological adjuvants: a role for liposomes. Immunology Today 1990 11 3 89 97 2-s2.0-0025129271 (Pubitemid 20062716)
155. Alving C. R., Liposomes as carriers of antigens and adjuvants. Journal of Immunological Methods 1991 140 1 1 13 2-s2.0-0025854178 10.1016/0022-1759(91) 90120-5
156. Rosenkrands I., Vingsbo-Lundberg C., Bundgaard T. J., Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 2011 29 37 6283 6291
157. Agger E. M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B. S., Aagaard C., Werninghaus K., Kirschning C., Lang R., Christensen D., Theisen M., Follmann F., Andersen P., Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008 3 9 2-s2.0-52349119606 10.1371/journal.pone.0003116 e3116
158. World Health Organization, Malaria Vaccine Rainbow Tables (Dec 2012). 2012, http://www.who.int/vaccine-research/links/Rainbow//en/index.html
159. Ravi Kumar M. N., Nano and microparticles as controlled drug delivery devices. Journal of Pharmacy & Pharmaceutical Sciences 2000 3 2 234 258 2-s2.0-0034182386
160. Davis S. S., The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 2006 24 2, supplement S2 S10 2-s2.0-33645228369 10.1016/j.vaccine.2005. 01.102
161. McNeela E. A., Lavelle E. C., Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination. Current Topics in Microbiology and Immunology 2012 354 75 99
162. Salvador A., Igartua M., Hernandez R. M., Pedraz J. L., Combination of immune stimulating adjuvants with poly(lactide-co-glycolide) microspheres enhances the immune response of vaccines. Vaccine 2012 30 3 589 596
163. Kim K., Pack D., Microspheres for drug delivery. BioMEMs and Biomedical Nanotecnohlogy-Volume I: Biological and Biomedical Nanotechnology 2006 Springer 19 49
164. Anderson J. M., Shive M. S., Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 1997 28 1 5 24 2-s2.0-0343247711 10.1016/S0169-409X(97)00048-3 (Pubitemid 27497671)
165. Wang W., Singh M., Selection of adjuvants for enhanced vaccine potency. World Journal of Vaccines 2011 1 33 78
166. Johansen P., Men Y., Merkle H. P., Gander B., Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. European Journal of Pharmaceutics and Biopharmaceutics 2000 50 1 129 146 2-s2.0-0034601247 10.1016/S0939-6411(00)00079-5 (Pubitemid 30326693)
167. Mata E., Carcaboso A. M., Hernández R. M., Igartua M., Corradin G., Pedraz J. L., Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine 2007 25 5 877 885 2-s2.0-33845198476 10.1016/j.vaccine.2006.09. 036 (Pubitemid 44856124)
168. Men Y., Tamber H., Audran R., Gander B., Corradin G., Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine 1997 15 12-13 1405 1412 2-s2.0-0030883026 10.1016/S0264-410X(97)00047-9 (Pubitemid 27397821)
169. Carcaboso A. M., Hernández R. M., Igartua M., Rosas J. E., Patarroyo M. E., Pedraz J. L., Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 2004 22 11-12 1423 1432 2-s2.0-1842613560 10.1016/j.vaccine.2003.10.020 (Pubitemid 38446918)
170. Carcaboso A. M., Hernández R. M., Igartua M., Gascón A. R., Rosas J. E., Patarroyo M. E., Pedraz J. L., Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. International Journal of Pharmaceutics 2003 260 2 273 282 2-s2.0-0038121685 10.1016/S0378-5173(03)00266-7 (Pubitemid 36773924)
171. Newman K. D., Elamanchili P., Kwon G. S., Samuel J., Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. Journal of Biomedical Materials Research 2002 60 3 480 486
172. Tizard I. R., Carpenter R. H., McAnalley B. H., Kemp M. C., The biological activities of mannans and related complex carbohydrates. Molecular Biotherapy 1989 1 6 290 296 2-s2.0-0024839250
173. Silva D. G., Cooper P. D., Petrovsky N., Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunology and Cell Biology 2004 82 6 611 616 2-s2.0-9444239833 10.1111/j.1440-1711.2004.01290.x (Pubitemid 39563962)
174. O'Neill L. A. J., Bryant C. E., Doyle S. L., Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacological Reviews 2009 61 2 177 197 2-s2.0-67649422321 10.1124/pr.109.001073
175. Corden K. B., Gorski K. S., Gibson S. J., Kedl R. M., Kieper W. C., Qiu X., Tomai M. A., Alkan S. S., Vasilakos J. P., Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. Journal of Immunology 2005 174 3 1259 1268 2-s2.0-12444341806
176. Mbow M. L., De Gregorio E., Valiante N. M., Rappuoli R., New adjuvants for human vaccines. Current Opinion in Immunology 2010 22 3 411 416 2-s2.0-77953534296 10.1016/j.coi.2010.04.004
177. Chang B. A., Cross J. L., Najar H. M., Dutz J. P., Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 2009 27 42 5791 5799 2-s2.0-69749086126 10.1016/j.vaccine.2009.07.062
178. Miranda-Verástegui C., Llanos-Cuentas A., Arévalo I., Ward B. J., Matlashewski G., Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clinical Infectious Diseases 2005 40 10 1395 1403 2-s2.0-18244373947 10.1086/429238 (Pubitemid 40628625)
179. Othoro C., Johnston D., Lee R., Soverow J., Bystryn J. C., Nardin E., Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic toll-like receptor 7 agonist, imiquimod. Infection and Immunity 2009 77 2 739 748 2-s2.0-60549088105 10.1128/IAI.00974-08
180. Hayashi F., Smith K. D., Ozinsky A., Hawn T. R., Yi E. C., Goodlett D. R., Eng J. K., Akira S., Underhill D. M., Aderem A., The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001 410 6832 1099 1103 2-s2.0-0035953543 10.1038/35074106 (Pubitemid 32391041)
181. Bargieri D. Y., Rosa D. S., Braga C. J. M., Carvalho B. O., Costa F. T. M., Espíndola N. M., Vaz A. J., Soares I. S., Ferreira L. C. S., Rodrigues M. M., New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 2008 26 48 6132 6142 2-s2.0-55049115986 10.1016/j.vaccine. 2008.08.070
182. Bargieri D. Y., Leite J. A., Lopes S. C. P., Sbrogio-Almeida M. E., Braga C. J. M., Ferreira L. C. S., Soares I. S., Costa F. T. M., Rodrigues M. M., Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella Typhimurium. Vaccine 2010 28 16 2818 2826 2-s2.0-77949658432 10.1016/j.vaccine.2010.02.004
183. Braga C. J. M., Massis L. M., Sbrogio-Almeida M. E., Alencar B. C. G., Bargieri D. Y., Boscardin S. B., Rodrigues M. M., Ferreira L. C. S., CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 2010 28 5 1373 1382 2-s2.0-74149087014 10.1016/j.vaccine.2009.11.003
184. Matsumoto M., Seya T., TLR3: interferon induction by double-stranded RNA including poly(I:C). Advanced Drug Delivery Reviews 2008 60 7 805 812 2-s2.0-41349102954 10.1016/j.addr.2007.11.005
185. + T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and α DEC-CSP in non human primates. Vaccine 2010 28 45 7256 7266 2-s2.0-77957753966 10.1016/j.vaccine.2010.08.098
186. Robinson R. A., DeVita V. T., Levy H. B., A phase I II trial of multiple dose polyriboinosinic polyribocytidylic acid in patients with leukemia or solid tumors. Journal of the National Cancer Institute 1976 57 3 599 602 2-s2.0-0017108014
187. Lousada-Dietrich S., Jogdand P. S., Jepsen S., Pinto V. V., Ditlev S. B., Christiansen M., Larsen S. O., Fox C. B., Raman V. S., Howard R. F., Vedvick T. S., Ireton G., Carter D., Reed S. G., Theisen M., A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2-A GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011 29 17 3284 3292 2-s2.0-79954606125 10.1016/j.vaccine.2011.02.022
188. Meraldi V., Audran R., Romero J. F., Brossard V., Bauer J., López J. A., Corradin G., OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 2003 21 19-20 2485 2491 2-s2.0-0037726802 10.1016/S0264-410X(03)00093-8 (Pubitemid 36561340)
189. Olafsdottir T. A., Lingnau K., Nagy E., Jonsdottir I., IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scandinavian Journal of Immunology 2009 69 3 194 202 2-s2.0-60349123505 10.1111/j.1365-3083.2008.02225.x
190. Schellack C., Prinz K., Egyed A., Fritz J. H., Wittmann B., Ginzler M., Swatosch G., Zauner W., Kast C., Akira S., von Gabain A., Buschle M., Lingnau K., IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006 24 26 5461 5472 2-s2.0-33744806358 10.1016/j.vaccine.2006.03.071 (Pubitemid 43831376)
191. Blom A. G., Hilgers L. A. T., Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition. Vaccine 2004 23 6 743 754 2-s2.0-8144228278 10.1016/j.vaccine.2004.07.021 (Pubitemid 39473172)
192. Hilgers L. A. T., Blom A. G., Sucrose fatty acid sulphate esters as novel vaccine adjuvant. Vaccine 2006 24 2 S81 S82 2-s2.0-33645241673 10.1016/j.vaccine.2005.01.133
193. Bodewes R., Geelhoed-Mieras M. M., Heldens J. G. M., Glover J., Lambrecht B. N., Fouchier R. A. M., Osterhaus A. D. M. E., Rimmelzwaan G. F., The novel adjuvant CoVaccineHT ™ increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro. Vaccine 2009 27 49 6833 6839 2-s2.0-70449102682 10.1016/j.vaccine.2009.09.015
194. Kusi K. A., Remarque E. J., Riasat V., Walraven V., Thomas A. W., Faber B. W., Kocken C. H., Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques. Malaria Journal 2011 10, article 182 2-s2.0-79959776666 10.1186/1475-2875-10-182
195. Mahdi Abdel H. M., Remarque E. J., van Duivenvoorde L. M., Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS One 2011 6 5 e20547
196. Lin K. H., Liang J. J., Huang W. I., Lin-Chu S. Y., Su C. Y., Lee Y. L., Jan J. T., Lin Y. L., Cheng Y. S. E., Wong C. H., In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models. Antimicrobial Agents and Chemotherapy 2010 54 10 4129 4136 2-s2.0-77957348634 10.1128/AAC.00368-10
197. Li X., Fujio M., Imamura M., Wu D., Vasan S., Wong C. H., Ho D. D., Tsuji M., Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proceedings of the National Academy of Sciences of the United States of America 2010 107 29 13010 13015 2-s2.0-77955632252 10.1073/pnas.1006662107
198. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C. C., Wilson J. M., Schmieg J., Kronenberg M., Nakayama T., Taniguchi M., Koezuka Y., Tsuji M., Natural killer T cell ligand α -galactosylceramide enhances protective immunity induced by malaria vaccines. Journal of Experimental Medicine 2002 195 5 617 624 2-s2.0-0037018103 10.1084/jem.20011889 (Pubitemid 34461506)
199. Padte N. N., Li X., Tsuji M., Vasan S., Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clinical Immunology 2011 140 2 142 151 2-s2.0-79960471413 10.1016/j.clim.2010.11.009
200. Pérez O., Lastre M., Cabrera O., Del Campo J., Bracho G., Cuello M., Balboa J., Acevedo R., Zayas C., Gil D., Mora N., González D., Pérez R., González E., Barberá R., Fajardo E. M., Sierra G., Solís R. L., Campa C., New vaccines require potent adjuvants like AFPL1 and AFCo1. Scandinavian Journal of Immunology 2007 66 2-3 271 277 2-s2.0-34447328136 10.1111/j.1365-3083.2007.01981.x (Pubitemid 47063207)
201. Bracho G., Zayas C., Wang L., Coppel R., AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malaria Journal 2009 8 1, article 35 2-s2.0-63849236862 10.1186/1475-2875-8-35
202. Harandi A. M., Davies G., Olesen O. F., Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Review of Vaccines 2009 8 3 293 298 2-s2.0-63849177560 10.1586/14760584.8.3.293
203. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A., Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunology 2005 6 8 769 776 2-s2.0-23944489407 10.1038/ni1223 (Pubitemid 43090462)
204. Zhu Q., Egelston C., Vivekanandhan A., Uematsu S., Akira S., Klinman D. M., Belyakov I. M., Berzofsky J. A., Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proceedings of the National Academy of Sciences of the United States of America 2008 105 42 16260 16265 2-s2.0-55849138791 10.1073/pnas.0805325105
205. Merlo A., Calcaterra C., Ménard S., Balsari A., Cross-talk between Toll-like receptors 5 and 9 on activation of human immune responses. Journal of Leukocyte Biology 2007 82 3 509 518 2-s2.0-34548388000 10.1189/jlb.0207100 (Pubitemid 47367141)
206. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., O'Hagan D. T., Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. Journal of Controlled Release 2006 110 3 566 573 2-s2.0-31644446786 10.1016/j.jconrel.2005.10.010 (Pubitemid 43168189)
207. Wischke C., Zimmermann J., Wessinger B., Schendler A., Borchert H. H., Peters J. H., Nesselhut T., Lorenzen D. R., Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. International Journal of Pharmaceutics 2009 365 1-2 61 68 2-s2.0-57049158142 10.1016/j.ijpharm.2008.08.039
208. World Health Organization, World Malaria Report 2011 (WHO Global Malaria Programme). 2012, http://apps.who.int/iris/bistream/10665/44792/2/9789241564403- eng- full.pdf